Posted by Michael Wonder on 11 Jan 2018
Institute for Clinical and Economic Review posts draft scoping document on elagolix for endometriosis
11 January 2018 - Document open to public comment until 1 February 2018.
The ICER has posted a draft scoping document outlining a planned review of elagolix (AbbVie/Neurocrine Biosciences) for the treatment of endometriosis and associated pain. The scoping document will be open to public comment for three weeks until 5 pm ET on 1 February 2018.
Elagolix is currently under review by the FDA, with an approval decision expected by mid-2018. The report will be subject to deliberation during a public meeting of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC), one of ICER's three independent evidence appraisal committees, in July of 2018.
